Schlatzer, Daniela

Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo

Najm, F. J., Madhavan, M., Zaremba, A., Shick, E., Karl, R. T., Factor, D. C., Miller, T. E., Nevin, Z. S., Kantor, C., Sargent, A., et al. (2015) · Nature

Multiple Sclerosis Research StudiesNeurogenesis and neuroplasticity mechanisms

Cited by 424

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth

Sangodkar, J., Perl, A., Tohme, R., Kiselar, J., Kastrinsky, D. B., Zaware, N., Izadmehr, S., Mazhar, S., Wiredja, D. D., O’Connor, C. M., et al. (2017) · Journal of Clinical Investigation

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 196

Selective PP2A enhancement through biased heterotrimer stabilization

Leonard, D., Huang, W., Izadmehr, S., O’Connor, C. M., Wiredja, D. D., Wang, Z., Zaware, N., Chen, Y., Schlatzer, D. M., Kiselar, J., et al. (2020) · Cell

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 176

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer

McClinch, K., Avelar, R. A., Callejas, D., Izadmehr, S., Wiredja, D., Perl, A., Sangodkar, J., Kastrinsky, D. B., Schlatzer, D., Cooper, M., et al. (2018) · Cancer Research

Prostate Cancer Treatment and ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 78

Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors

O’Connor, C. M., Leonard, D., Wiredja, D., Avelar, R. A., Wang, Z., Schlatzer, D., Bryson, B., Tokala, E., Taylor, S. E., Upadhyay, A., et al. (2020) · Oncogene

Protein Tyrosine PhosphatasesMelanoma and MAPK Pathways

Cited by 48